Selegiline stimulates biosynthesis of cytokines interleukin-1β and interleukin-6

Kuhn Wilfried*, Thomas Müller, Rejko Krüger, Przuntek Horst

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

9 Citations (Scopus)


SEVERAL lines of evidence indicate an immune-mediated pathophysiology of Parkinson's disease (PD) and Alzheimer's disease (AD). In clinical studies the monoamine oxidase-B inhibitor Selegiline appears to slow the progression of neurological deficits in PD and the cognitive decline in AD. The immune response to bacterial or viral infection and in chronic inflammatory processes is stimulated by an increased synthesis of the cytokines interleukin-1β (IL-1β) and subsequently interleukin-6 (IL-6). We investigated the influence of Selegiline on the synthesis of IL-1β and IL-6 in peripheral blood mononuclear cells (PBMC) from healthy blood donors cultured with or without Selegiline (10-8 M, 10-9 M or 10-10 M) in a humidified atmosphere (7% CO2). Treatment of cultured PBMC with Selegiline significantly increased synthesis of both cytokines. The effect of Selegiline on cytokine biosynthesis may contribute to its putative neuroprotective properties.

Original languageEnglish
Pages (from-to)2847-2848
Number of pages2
Issue number18
Publication statusPublished - 1996
Externally publishedYes


  • Biosynthesis
  • Interleukin 6
  • Interleukin-1β
  • Parkinson's disease
  • Selegiline


Dive into the research topics of 'Selegiline stimulates biosynthesis of cytokines interleukin-1β and interleukin-6'. Together they form a unique fingerprint.

Cite this